Canadian council helps fund Arch Biopartners brain tumor research
The National Research Council of Canada—Industrial Research Assistance Program (NRC-IRAP) has approved funding up to $107,000 to assist Arch Biopartners in the development of diagnostic imaging applications for its brain tumor initiating cell targeting technology.
Arch Cancer Therapeutics, a subsidiary of Toronto-based Arch Biopartners, is currently working with NRC-IRAP to develop prototype brain tumor initiating cell diagnostic imaging agents for use in MRI. The company anticipates that the assistance will allow Arch to complete prototype development of the technology within the next 12 months.
Brain tumor initiating cells are a cancer stem cell population believed to play an important role in the formation and recurrence of malignant glioma in humans, though they are not detected by current diagnostic imaging technologies.
Arch Cancer Therapeutics, a subsidiary of Toronto-based Arch Biopartners, is currently working with NRC-IRAP to develop prototype brain tumor initiating cell diagnostic imaging agents for use in MRI. The company anticipates that the assistance will allow Arch to complete prototype development of the technology within the next 12 months.
Brain tumor initiating cells are a cancer stem cell population believed to play an important role in the formation and recurrence of malignant glioma in humans, though they are not detected by current diagnostic imaging technologies.
Evan Godt, Writer
Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.